Glial fibrillary acidic protein: a blood biomarker to differentiate neurodegenerative from psychiatric diseases
- 3 September 2021
- journal article
- editorial
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 92 (12), 1253
- https://doi.org/10.1136/jnnp-2021-326994
Abstract
To facilitate biomarker-based detection of neurodegeneration in clinical practice, easy-to-use blood tests for first-line testing would be of great value. Such tests have been developed for Alzheimer’s disease pathology (plasma Aβ42/Aβ40 ratio and phosphorylated tau species), and for neurofilament light (NfL), a more general biomarker for neuroaxonal injury in both acute and chronic neurological conditions has been developed.1 In contrast, it has been difficult to identify biomarkers for psychiatric diseases—none exists to date and the most general biomarker NfL is negative.This publication has 4 references indexed in Scilit:
- Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s diseaseBrain, 2021
- GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performanceJournal of Neurology, Neurosurgery & Psychiatry, 2021
- Relevance of biomarkers across different neurodegenerative diseasesAlzheimer's Research & Therapy, 2020
- A sensitive ELISA for glial fibrillary acidic protein: application in CSF of childrenJournal of Neuroscience Methods, 1992